Literature DB >> 25092790

p38 links RAS to GATA2.

Christian Baumgartner1, Manuela Baccarini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25092790      PMCID： PMC4198032          DOI： 10.15252/embr.201439309

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  10 in total

Review 1.  The role of the GATA2 transcription factor in normal and malignant hematopoiesis.

Authors:  Carmen Vicente; Ana Conchillo; María A García-Sánchez; María D Odero
Journal:  Crit Rev Oncol Hematol       Date:  2011-05-24       Impact factor: 6.312

Review 2.  Drugging the undruggable: transcription therapy for cancer.

Authors:  Chunhong Yan; Paul J Higgins
Journal:  Biochim Biophys Acta       Date:  2012-11-09

3.  Molecular basis of crosstalk between oncogenic Ras and the master regulator of hematopoiesis GATA-2.

Authors:  Koichi R Katsumura; Chenxi Yang; Meghan E Boyer; Lingjun Li; Emery H Bresnick
Journal:  EMBO Rep       Date:  2014-07-23       Impact factor: 8.807

Review 4.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

5.  The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Authors:  Madhu S Kumar; David C Hancock; Miriam Molina-Arcas; Michael Steckel; Phillip East; Markus Diefenbacher; Elena Armenteros-Monterroso; François Lassailly; Nik Matthews; Emma Nye; Gordon Stamp; Axel Behrens; Julian Downward
Journal:  Cell       Date:  2012-04-27       Impact factor: 41.582

Review 6.  Dragging ras back in the ring.

Authors:  Andrew G Stephen; Dominic Esposito; Rachel K Bagni; Frank McCormick
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

7.  A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche.

Authors:  Yoon-Young Jang; Saul J Sharkis
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

8.  Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.

Authors:  M Ogrunc; R Di Micco; M Liontos; L Bombardelli; M Mione; M Fumagalli; V G Gorgoulis; F d'Adda di Fagagna
Journal:  Cell Death Differ       Date:  2014-02-28       Impact factor: 15.828

9.  GATA-3 regulates the self-renewal of long-term hematopoietic stem cells.

Authors:  Catherine Frelin; Robert Herrington; Salima Janmohamed; Mary Barbara; Gary Tran; Christopher J Paige; Patricia Benveniste; Juan-Carlos Zuñiga-Pflücker; Abdallah Souabni; Meinrad Busslinger; Norman N Iscove
Journal:  Nat Immunol       Date:  2013-08-25       Impact factor: 25.606

10.  Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Authors:  Natacha Bohin; Tiffany Wen; Qing Li; Victor Ng; Jeffrey Magee; Shann-Ching Chen; Kevin Shannon; Sean J Morrison
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962
  10 in total
  4 in total

Review 1.  The role of GATA2 in lethal prostate cancer aggressiveness.

Authors:  Veronica Rodriguez-Bravo; Marc Carceles-Cordon; Yujin Hoshida; Carlos Cordon-Cardo; Matthew D Galsky; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2016-11-22       Impact factor: 14.432

2.  p38 activation induces production of miR-146a and miR-31 to repress E-selectin expression and inhibit transendothelial migration of colon cancer cells.

Authors:  Liang Zhong; Jacques Huot; Martin J Simard
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

3.  p38 and JNK pathways control E-selectin-dependent extravasation of colon cancer cells by modulating miR-31 transcription.

Authors:  Liang Zhong; Bryan Simoneau; Jacques Huot; Martin J Simard
Journal:  Oncotarget       Date:  2017-01-03

4.  GATA2 regulates the erythropoietin receptor in t(12;21) ALL.

Authors:  Marie E Gaine; Daniel J Sharpe; James S Smith; Hilary A A Colyer; Vivien M Hodges; Terry R Lappin; Ken I Mills
Journal:  Oncotarget       Date:  2017-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.